2d illustrations and photos/iStock via Getty Images HashiCorp (NASDAQ:HCP) and IBM (NYSE:IBM) have acknowledged the receipt of a second request for information from the Federal Trade Commission over its antitrust probe of their merger. IBM in late April agreed to buy HashiCorp for $35 a share in cash. The twoContinue Reading
Nano Labs (NASDAQ:NA) announced that it received a notification letter dated July 11, 2024 from Nasdaq notifying that the company is no longer in compliance with the Nasdaq Listing Rule. The Deficiency Letter does not result in the immediate delisting of the Company’s Class A ordinary shares on the Nasdaq GlobalContinue Reading
Grand Cayman, Cayman Islands, July 9th, 2024, Chainwire In a step forward for the derivatives ecosystem on Arbitrum, two prominent DeFi projects, GMX and Gains Network, have unveiled bids to integrate their platforms into Kwenta’s upcoming perpetuals marketplace. Kwenta, the leading perpetual futures exchange on Optimism, expanded its reach earlierContinue Reading
solarseven/iStock via Getty Images Hempacco (NASDAQ:HPCO) said it has received a notice from Nasdaq, advising the company that it has initiated a process to delist its securities from Nasdaq because the company had not filed its annual report on Form 10-K for the year ended Dec. 31, 2023, and quarterly reportContinue Reading
“We downgrade the stock to Neutral today, as upside will only materialize in a bull case, in which the outlook beyond 2025 increases materially, and we do not have the conviction on this scenario playing out yet,” said New Street analyst Pierre Ferragu in a report on Friday. The firmContinue Reading
skynesher/E+ via Getty Images Psyence Biomedical (NASDAQ:PBM) said Wednesday it received a letter from Nasdaq for not meeting the minimum bid price of $1.00 per share required for continued listing. Psyence Biomedical (PBM) has 180 calendar days, or until December 24, 2024 to regain compliance with the Minimum Bid Price Rule. Source: Press Release MoreContinue Reading
Mohammed Haneefa Nizamudeen Health Canada has authorized Johnson & Johnson’s (NYSE:JNJ) Rybrevant (amivantamab) along with platinum-based chemotherapy as a first-line treatment for non-small cell lung with a certain mutation. The authorization is for patients with EGFR Exon 20 insertion mutations. The approval was supported by data from the phase 3Continue Reading
Sharps Technology (NASDAQ:STSS) has received two purchase orders for a total of ~1M SecureGard ultra-low waste smart safety syringes produced at Sharps’ manufacturing facility in Hungary. The first 100k syringe shipment is scheduled for the third week of July, and subsequent deliveries will be made throughout the rest of 2024.Continue Reading
Justin Sullivan/Getty Images News Apple (NASDAQ:AAPL) is apparently receiving an observer role position on OpenAI’s board of directors, according to a report Tuesday afternoon by Bloomberg, which cited anonymous sources close to the situation. The position is going to Phil Schiller, a 30-year Apple veteran who currently leads the AppContinue Reading
Ideanomics (NASDAQ:IDEX) on Tuesday said it has received a notice from Nasdaq, stating that because the company’s Form 10-K for the fiscal year ended December 31, 2023, reported stockholders’ equity of less than the required minimum of $2,500,000 in stockholders’ equity for continued listing, and as of that day, theContinue Reading
